Results 181 to 190 of about 119,989 (312)

Progress in Biomimetic Microdevices for Anticancer Drug Screening and their Potential for Enhancing In Vivo Efficacy

Advanced NanoBiomed Research, EarlyView.
Biomimetic microdevices are redefining anticancer drug screening by mimicking complex tumor microenvironments. This review highlights advances in microfluidic systems, cell microarrays, and in vivo‐like models, offering new insights into drug efficacy prediction and personalized medicine. The development of effective anticancer drugs remains a critical
Ching‐Te Kuo, Yen‐Tzu Liao, Hsinyu Lee   +2 more
wiley   +1 more source

Go to the scene: T_H9 cells superior migration ability to the lungs explains their exceptional anticancer efficacy. [PDF]

J Immunother Cancer
Xu J, Apetoh L.
europepmc   +1 more source

Natural Killer Cells in Cancer Immunotherapy [PDF]

, 2019
Arndt MA, Chester C, Cortez VS, D'Andrea A, Elsasser D, Ferrini S, Gao Y, Hartmann F, Lotze MT, Miller JS, Orr MT, Seillet C, Soiffer RJ, Soto EO, Weiner LM, Yron I   +15 more
core   +1 more source

Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy

Cell Reports
Summary: Adoptive cell therapies are emerging forms of immunotherapy that reprogram T cells for enhanced antitumor responses. Although surface programmed cell death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) engagement inhibits antitumor ...
Xinran Wang, Lu Lu, Xiaochuan Hong, Lingling Wu, Chao Yang, You Wang, Wenwen Li, Yuanqin Yang, Dongqing Cao, Wen Di, Liufu Deng   +10 more
doaj  

Expanding horizons of cancer immunotherapy: hopes and hurdles. [PDF]

Front Oncol
Sonar PV, Singh AK, Mandadi S, Sharma NK.   +3 more
europepmc   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Can Adoptive Immunotherapy With Hepatitis E Virus (HEV)-Specific T Cells Address the Unmet Need in Refractory Chronic HEV Infection? [PDF]

Open Forum Infect Dis
Lampejo T.
europepmc   +1 more source

Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation. [PDF]

Explor Target Antitumor Ther
Naffaa MM, Al-Ewaidat OA, Gogia S, Begiashvili V.   +3 more
europepmc   +1 more source

Paradoxical Activation of Entheseal Myeloid Cells by JAK1 and TYK2 Inhibitors via IL10 Antagonism

Arthritis &Rheumatology, Accepted Article.
Background JAK inhibition (JAKi) is effective in seronegative spondyloarthropathy (SpA) spectrum disorders, but TYK2 inhibition failed in SpA spectrum ulcerative colitis, and tofacitinib showed minimal benefit in Crohn's Disease, which highlights the complex role for JAK‐STAT signaling in different inflammatory processes. In this study, we investigated
Sami Giryes, Chi Wong, Charlie Bridgewood, Mark Harland, Ala Altaie, Nicole McDermott, Kerem Abacar, Abhay Rao, Almas Khan, Tristan McMillan, Peter Loughenbery, Robert Dunsmuir, Vishal Borse, Tom Macleod, Dennis McGonagle   +14 more
wiley   +1 more source